1. Efficacy of forskolin as a promising therapy for chronic olfactory dysfunction post COVID-19.
- Author
-
Abdelazim MH, Alsenani F, Alnuhait M, Alshammari AS, Altemani AH, Althagafi EA, Waggas DS, Abdelazim AH, and Alharbi A
- Subjects
- Humans, Male, Female, Middle Aged, Prospective Studies, Chronic Disease, Adult, Treatment Outcome, Aged, SARS-CoV-2, Double-Blind Method, Colforsin therapeutic use, Colforsin administration & dosage, COVID-19 complications, Olfaction Disorders drug therapy, Olfaction Disorders etiology
- Abstract
Purpose: Olfactory dysfunction is increasingly common among COVID-19 patients, impacting their well-being. Reports have demonstrated decreased levels of cyclic adenosine monophosphate and cyclic guanosine monophosphate among patients with chronic olfactory dysfunction. A prospective randomized clinical trial was developed to demonstrate the efficacy of an oral forskolin regimen treatment, an adenylyl cyclase activator that raises intracellular levels of cyclic adenosine monophosphate, for the treatment of olfactory dysfunction following COVID-19, compared to placebo regimen., Methods: The study enrolled 285 participants with persistent olfactory dysfunction post COVID-19 infection, randomly assigning them to receive either placebo capsules (n = 120) or oral forskolin capsules (n = 165). Follow-up was conducted to track progress, with 18 participants from the placebo group and 12 from the forskolin group lost during this period. Olfactory function was assessed using the "Sniffin' Sticks" test, measuring threshold, discrimination and identification scores before and after treatment., Results: Subjects administered forskolin capsules demonstrated a significant enhancement in their composite TDI (threshold, discrimination and identification) score, suggesting a notable amelioration in olfactory functionality. Moreover, the discrimination and identification scores notably improved within the forskolin group. Conversely, no significant alterations were observed in the threshold scores., Conclusion: This study suggests that forskolin can contribute potentially to improve chronic olfactory dysfunction post COVID-19., Trial Registration: DFM-IRB00012367-23-10-001., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF